Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV

Pharmacotherapy
Bhavik M ShahJoseph A Desimone

Abstract

The first two integrase strand transfer inhibitors (INSTIs) approved for treatment of patients infected with human immunodeficiency virus (HIV) were raltegravir and elvitegravir. Both raltegravir and elvitegravir are now guideline-preferred agents as part of an antiretroviral regimen for treatment-naive patients. However, raltegravir is dosed twice/day. Elvitegravir is available in a single-tablet regimen and dosed once/day because it is administered with the pharmacokinetic booster cobicistat, a potent CYP3A4 inhibitor that can lead to clinically significant drug-drug interactions. In addition, raltegravir and elvitegravir have a low genetic barrier to resistance and are associated with cross-resistance. Dolutegravir is a new-generation INSTI administered once/day without a pharmacokinetic booster and can be coformulated in a single-tablet regimen. Phase III studies have demonstrated the efficacy and safety of dolutegravir for treatment-naive and treatment-experienced patients. Compared with other INSTIs, dolutegravir has a higher genetic barrier to resistance. Dolutegravir was approved by the U.S. Food and Drug Administration in August 2013 and joins raltegravir and elvitegravir as guideline-preferred agents for the managemen...Continue Reading

References

Aug 29, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Edwin DeJesusUNKNOWN 183-0101 Study Team
Aug 24, 2007·Clinical Pharmacology and Therapeutics·M IwamotoJ A Wagner
Jul 25, 2008·The New England Journal of Medicine·Roy T SteigbigelUNKNOWN BENCHMRK Study Teams
Jul 25, 2008·The New England Journal of Medicine·David A CooperUNKNOWN BENCHMRK Study Teams
Oct 22, 2008·Annual Review of Pharmacology and Toxicology·Daria HazudaLarissa Wenning
Nov 4, 2009·Antimicrobial Agents and Chemotherapy·Sherene MinStephen C Piscitelli
Dec 3, 2009·The New England Journal of Medicine·Paul E SaxUNKNOWN AIDS Clinical Trials Group Study A5202 Team
Jun 30, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Ivy SongStephen C Piscitelli
May 11, 2011·Antimicrobial Agents and Chemotherapy·Ivy SongStephen C Piscitelli
Jun 23, 2011·Infection and Drug Resistance·Jean L MbisaPatricia A Cane
Sep 17, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jürgen K RockstrohUNKNOWN STARTMRK Investigators
Dec 21, 2011·Antimicrobial Agents and Chemotherapy·Ivy SongStephen C Piscitelli
Mar 9, 2013·Pharmacotherapy·Bhavik M ShahKathleen E Squires
Nov 8, 2013·The New England Journal of Medicine·Sharon L WalmsleyUNKNOWN SINGLE Investigators
May 20, 2014·British Journal of Clinical Pharmacology·Mark JohnsonStephen Piscitelli
Jul 20, 2014·JAMA : the Journal of the American Medical Association
Aug 27, 2014·Antimicrobial Agents and Chemotherapy·Ivy SongStephen C Piscitelli

❮ Previous
Next ❯

Citations

Nov 11, 2015·Drug Development and Industrial Pharmacy·Julia Anita GrießingerAndreas Bernkop-Schnürch
Mar 18, 2017·BMC Infectious Diseases·Franco MaggioloCristina Mussini
Jul 25, 2017·Journal of Medicinal Chemistry·Xue Zhi ZhaoTerrence R Burke
Jul 2, 2014·Therapeutic Advances in Chronic Disease·Alessandra Fantauzzi, Ivano Mezzaroma
May 19, 2018·Expert Review of Clinical Pharmacology·Jose L CasadoMiguel A Rodriguez-Sagrado
Feb 15, 2018·The Annals of Pharmacotherapy·Rosaleen BoswellChristine A Hughes
Jan 23, 2020·Current HIV/AIDS Reports·Jay TrivediSiddappa N Byrareddy
Sep 2, 2017·The Journal of Antimicrobial Chemotherapy·Christoph D SpinnerChristoph Boesecke
Nov 27, 2018·The Journal of Antimicrobial Chemotherapy·Véronique JolyUNKNOWN LAMIDOL Study Group
Jul 28, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Xue Zhi ZhaoTerrence R Burke
Apr 11, 2018·Expert Opinion on Investigational Drugs·Tristan D McPhersonMartin Markowitz
Jan 26, 2021·AIDS Research and Human Retroviruses·Daniele Di CarloOmbretta Turriziani
Feb 23, 2021·ACS Pharmacology & Translational Science·Herana Kamal SeneviratneNamandjé N Bumpus
Jun 29, 2021·Expert Opinion on Emerging Drugs·Marco PiscagliaGiuliano Rizzardini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.